Gommlich, A.
Raschke, F. http://orcid.org/0000-0002-1054-9609
Petr, J.
Seidlitz, A.
Jentsch, C.
Platzek, I.
van den Hoff, J.
Kotzerke, J.
Beuthien-Baumann, B.
Baumann, M.
Krause, M.
Troost, E. G. C.
Funding for this research was provided by:
Helmholtz-Zentrum Dresden - Rossendorf e. V.
Article History
Received: 12 November 2020
Revised: 11 March 2021
Accepted: 16 March 2021
First Online: 31 March 2021
Declarations
:
: In the past 5 years, Dr. Michael Baumann received funding for his research projects and for educational grants to the University of Dresden by Bayer AG (2016–2018), Merck KGaA (2014-open) and Medipan GmbH (2014–2018). He is on the supervisory board of HI-STEM gGmbH (Heidelberg) for the German Cancer Research Center (DKFZ, Heidelberg) and also member of the supervisory body of the Charité University Hospital, Berlin. As former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), he has been or is responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he has discussed potential projects and signed contracts for research funding and/or collaborations with industry and academia for his institute(s) and staff, including but not limited to pharmaceutical companies such as Bayer, Boehringer Ingelheim, Bosch, Roche and other companies such as Siemens, IBA, Varian, Elekta, Bruker, etc. In this role, he was/is also responsible for the commercial technology transfer activities of his institute(s), including the creation of start-ups and licensing. This includes the DKFZ-PSMA617 related patent portfolio [WO2015055318 (A1), ANTIGEN (PSMA)] and similar IP portfolios. Dr. Baumann confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Within the past years, Dr. Krause received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018), Attomol GmbH (2019–2021), GA Generic Assays GmbH (2019–2021), BTU Cottbus-Senftenberg (2019–2021), Gesellschaft für medizinische und wissenschaftliche genetische Analysen (2019–2021), Lipotype GmbH (2019–2021), PolyAn GmbH (2019–2021). In the past 5 years, Dr. Troost has been involved in an ongoing publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019–2021). Dr. Baumann, Dr. Krause and Dr. Troost confirm that to the best of their knowledge none of the above funding sources were involved in the preparation of this paper. The other authors have nothing to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.